Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Homo sapiens | hydroxyprostaglandin dehydrogenase 15-(NAD) | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | steroid dehydrogenase, putative | hydroxyprostaglandin dehydrogenase 15-(NAD) | 266 aa | 216 aa | 22.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0.0303 | 0.5 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0021 | 0.0106 | 0.0114 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0947 | 0.1287 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0.0303 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0618 | 0.0774 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0303 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.9262 | 1 |
Schistosoma mansoni | zinc finger protein | 0.0024 | 0.0435 | 0.0546 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0303 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.736 | 1 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3258 | 0.4427 |
Echinococcus granulosus | zinc finger protein | 0.0024 | 0.0435 | 0.0592 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0.0303 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.4417 | 0.4769 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0303 | 0.0379 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0947 | 0.1188 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.0303 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.0303 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0303 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.0303 | 0.5 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.0303 | 0.0411 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.0303 | 0.5 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.3667 | 0.3469 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.0303 | 0.0327 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0025 | 0.0618 | 0.0667 |
Echinococcus multilocularis | zinc finger protein | 0.0024 | 0.0435 | 0.0592 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0303 | 0.0379 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0303 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0.0303 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.0303 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.3679 | 0.3972 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.0303 | 0.0411 |
Brugia malayi | PHD-finger family protein | 0.003 | 0.1356 | 0.1086 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.0303 | 0.5 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0947 | 0.1287 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.7978 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.4087 | 0.4413 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3258 | 0.4427 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.736 | 1 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.0303 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | > 50 um | PUBCHEM_BIOASSAY: Dose response cell-based high throughput screening assay to identify enhancers of beta-glucosidase activity. (Class of assay: confirmatory) [Related pubchem assays: 784 ] | ChEMBL. | No reference |
Potency (functional) | 0.631 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase). (Class of assay: confirmatory) [Related pubchem assays: 2429 (Confirmation qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2407 (Probe Development Summary for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2427 (Thermal Shift Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase))] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 26.6795 uM | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.